In summary, we have generated new chimeric antigen receptor NK cells by recruiting sPD-1 into HER2 and PD-L1 highly expressed breast cancer cells to improve the anticancer efficacy of HER2-CAR-NK in HER2-positive breast tumors, including trastuzumab-resistant breast cancer tumors. Here, CD274 is linked to breast carcinoma.